SHR-A1811 Clinical Trials
20 recruitingDrug
Phase 214Phase 35Phase 14
Showing 1–20 of 20 trials
Recruiting
Phase 2
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Metastatic Breast CancerAdvanced Breast Cancer
Fudan University160 enrolled1 locationNCT06649331
Recruiting
Phase 2
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
Metastatic Breast Cancer
Henan Cancer Hospital150 enrolled1 locationNCT05769010
Recruiting
Phase 2
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University200 enrolled1 locationNCT07340398
Recruiting
Phase 3
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
Non-Small Cell Lung Cancer With HER2- Mutations
Jiangsu HengRui Medicine Co., Ltd.300 enrolled1 locationNCT06430437
Recruiting
Phase 2
Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies
Antibody-drug ConjugatesAdvanced Solid Tumor CancerUrachal Cancer
Sheng Zhang90 enrolled1 locationNCT07309770
Recruiting
Phase 2
Reverse Triple Negative Immune Resistant Breast Cancer
Fudan University80 enrolled1 locationNCT05076682
Recruiting
Phase 1Phase 2
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
Ovarian Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.150 enrolled1 locationNCT06840002
Recruiting
Phase 2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Breast CancerBreast NeoplasmBreast Tumors
Fudan University716 enrolled1 locationNCT05582499
Recruiting
Phase 2
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Henan Cancer Hospital180 enrolled1 locationNCT06927180
Recruiting
Phase 1Phase 2
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.100 enrolled1 locationNCT06859775
Recruiting
Phase 3
A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Jiangsu HengRui Medicine Co., Ltd.1,600 enrolled2 locationsNCT06126640
Recruiting
Phase 1
Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer
Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.32 enrolled2 locationsNCT06710990
Recruiting
Phase 3
A Study of SHR-A1811 in Subjects With Ovarian Cancer
Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.300 enrolled2 locationsNCT06828354
Recruiting
Phase 2
A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.54 enrolled2 locationsNCT06778031
Recruiting
Phase 1Phase 2
Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis
Breast Cancer MetastaticBreast Cancer Brain Metastases
Fudan University74 enrolled1 locationNCT06718933
Recruiting
Phase 2
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Breast CancerBreast NeoplasmHER2-negative Breast Cancer+2 more
Fudan University620 enrolled1 locationNCT05594095
Recruiting
Phase 2
Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
HER2 Expression / Amplification in Patients With Biliary Tract Cancer
Jiangsu HengRui Medicine Co., Ltd.65 enrolled1 locationNCT06413745
Recruiting
Phase 2
A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
HER2-positive Breast Cancer
Shengjing Hospital65 enrolled1 locationNCT05635487
Recruiting
Phase 3
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Jiangsu HengRui Medicine Co., Ltd.360 enrolled1 locationNCT06123494
Recruiting
Phase 3
SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial
Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.530 enrolled1 locationNCT05814354